Articles by Tyler Sandahl, PharmD
From Satisfaction to Solutions: Unmet Needs, Future Regimens, and Anti-CD38 Formulary Management in NDMM
ByRyan Haumschild, PharmD, MS, MBA, CPEL,Tiffany Richards, PhD, APRN, ANP-BC, AOCNP,Jackson Gao, MD,Tyler Sandahl, PharmD The panelists examined the significant progress made in frontline multiple myeloma treatment while emphasizing that true satisfaction will only come when more patients achieve a durable cure and can transition off maintenance therapy entirely, identifying MRD-guided treatment discontinuation as one of the most promising pathways toward that goal.
Setting the Stage: The Most Significant Shifts in Frontline Multiple Myeloma Treatment
ByRyan Haumschild, PharmD, MS, MBA, CPEL,Tiffany Richards, PhD, APRN, ANP-BC, AOCNP,Jackson Gao, MD,Tyler Sandahl, PharmD Experts unpack new myeloma regimens—quadruplet induction, dual maintenance, earlier smoldering therapy—plus real-world access and cost hurdles.
